183 related articles for article (PubMed ID: 25084335)
1. Mapping the conformational space accessible to catechol-O-methyltransferase.
Ehler A; Benz J; Schlatter D; Rudolph MG
Acta Crystallogr D Biol Crystallogr; 2014 Aug; 70(Pt 8):2163-74. PubMed ID: 25084335
[TBL] [Abstract][Full Text] [Related]
2. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of the apo and holo form of rat catechol-O-methyltransferase.
Tsuji E; Okazaki K; Isaji M; Takeda K
J Struct Biol; 2009 Mar; 165(3):133-9. PubMed ID: 19111934
[TBL] [Abstract][Full Text] [Related]
4. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
Ellermann M; Paulini R; Jakob-Roetne R; Lerner C; Borroni E; Roth D; Ehler A; Schweizer WB; Schlatter D; Rudolph MG; Diederich F
Chemistry; 2011 May; 17(23):6369-81. PubMed ID: 21538606
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of human 108V and 108M catechol O-methyltransferase.
Rutherford K; Le Trong I; Stenkamp RE; Parson WW
J Mol Biol; 2008 Jun; 380(1):120-30. PubMed ID: 18486144
[TBL] [Abstract][Full Text] [Related]
6. Functional and structural characterization of a novel catechol-O-methyltransferase from Schizosaccharomyces pombe.
Wang Q; Teng M; Li X
IUBMB Life; 2019 Mar; 71(3):330-339. PubMed ID: 30501007
[TBL] [Abstract][Full Text] [Related]
7. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.
Ma Z; Liu H; Wu B
Br J Clin Pharmacol; 2014 Mar; 77(3):410-20. PubMed ID: 23713800
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of catechol O-methyltransferase.
Vidgren J; Svensson LA; Liljas A
Nature; 1994 Mar; 368(6469):354-8. PubMed ID: 8127373
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.
Tsuji E; Okazaki K; Takeda K
Biochem Biophys Res Commun; 2009 Jan; 378(3):494-7. PubMed ID: 19056347
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application.
Bonifácio MJ; Archer M; Rodrigues ML; Matias PM; Learmonth DA; Carrondo MA; Soares-Da-Silva P
Mol Pharmacol; 2002 Oct; 62(4):795-805. PubMed ID: 12237326
[TBL] [Abstract][Full Text] [Related]
11. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity.
Lerner C; Masjost B; Ruf A; Gramlich V; Jakob-Roetne R; Zürcher G; Borroni E; Diederich F
Org Biomol Chem; 2003 Jan; 1(1):42-9. PubMed ID: 12929389
[TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors.
Ellermann M; Lerner C; Burgy G; Ehler A; Bissantz C; Jakob-Roetne R; Paulini R; Allemann O; Tissot H; Grünstein D; Stihle M; Diederich F; Rudolph MG
Acta Crystallogr D Biol Crystallogr; 2012 Mar; 68(Pt 3):253-60. PubMed ID: 22349227
[TBL] [Abstract][Full Text] [Related]
13.
Czarnota S; Baxter NJ; Cliff MJ; Waltho JP; Scrutton NS; Hay S
Biomol NMR Assign; 2017 Apr; 11(1):57-61. PubMed ID: 27981425
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
[TBL] [Abstract][Full Text] [Related]
15. The 108M polymorph of human catechol O-methyltransferase is prone to deformation at physiological temperatures.
Rutherford K; Bennion BJ; Parson WW; Daggett V
Biochemistry; 2006 Feb; 45(7):2178-88. PubMed ID: 16475806
[TBL] [Abstract][Full Text] [Related]
16. A hotspot of inactivation: The A22S and V108M polymorphisms individually destabilize the active site structure of catechol O-methyltransferase.
Rutherford K; Daggett V
Biochemistry; 2009 Jul; 48(27):6450-60. PubMed ID: 19435324
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
Kiss LE; Soares-da-Silva P
J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080
[TBL] [Abstract][Full Text] [Related]
18. Prospecting for new catechol-
da Silva IR; Parise MR; Pereira M; da Silva RA
J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
[TBL] [Abstract][Full Text] [Related]
19. A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
Lanier M; Ambrus G; Cole DC; Davenport R; Ellery J; Fosbeary R; Jennings AJ; Kadotani A; Kamada Y; Kamran R; Matsumoto S; Mizukami A; Okubo S; Okada K; Saikatendu K; Walsh L; Wu H; Hixon MS
J Med Chem; 2014 Jun; 57(12):5459-63. PubMed ID: 24847974
[TBL] [Abstract][Full Text] [Related]
20. Detoxication of structurally diverse polycyclic aromatic hydrocarbon (PAH) o-quinones by human recombinant catechol-O-methyltransferase (COMT) via O-methylation of PAH catechols.
Zhang L; Jin Y; Chen M; Huang M; Harvey RG; Blair IA; Penning TM
J Biol Chem; 2011 Jul; 286(29):25644-54. PubMed ID: 21622560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
